Clinical Trial Update: Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of idelalisib in relapsed or refractory Hodgkin lymphoma has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-24